Document is current
Any future updates will be listed below
-
Authors
Kaeberlein, Tammi L.
Green, Alan S.
Haddad, George
Hudson, Johnny
Isman, Anar
Nyquist, Andy
Rosen, Bradley S.
Suh, Yousin
Zalzala, Sajad
Zhang, Xingyu
Blagosklonny, Mikhail V.
An, Jonathan Y.
Kaeberlein, Matt https://orcid.org/0000-0002-1311-3421
-
Funding
Funding for this research was provided by:
Longevity Impetus Grant from Norn Group
- License Information
-
More Information
Article History
Received: 6 March 2023
Accepted: 2 May 2023
First Online: 16 May 2023
Declarations
:
: MK and GH are co-founders of Optispan Geroscience, which has no material interest in rapamycin or rapamycin derivative production or sales at this time. ASG and BSR are practicing physicians who may prescribe rapamycin off-label for certain patients when appropriate. AI, AN, and SZ are employees and/or shareholders of AgelessRX, a longevity-focused telemedicine platform that sponsors several clinical trials, including interventional and observational efforts for the repurposed use of rapamycin.
